Oxysterol-Bisphosphonate Conjugates for Bone-Selective Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis, particularly in advanced cases, face limitations due to the low oral bioavailability and adverse side effects of bisphosphonate drugs, and the need for more effective anabolic agents to stimulate bone growth and reduce fracture risk.
Innovation Solution
Development of oxysterol-bisphosphonate conjugates, such as OXY133-alendronic acid, which selectively target bone tissue through the Hedgehog signaling pathway to enhance osteogenic differentiation and bone formation, addressing the limitations of existing therapies by improving pharmacological properties and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonate drugs are used for osteoporosis treatment, then bone resorption is inhibited and bone density is improved, but oral bioavailability is low and GI tract irritation occurs
Solution Approach 1:
The patent uses fatty acid conjugates as intermediary molecules that mask the phosphonate charge effect during oral administration. The fatty acid portion facilitates oral bioavailability by reducing GI tract irritation, while the phosphonate portion maintains bone-targeting capability. This intermediary structure resolves the contradiction between effective bone resorption inhibition and reduction of GI side effects.
Solution Approach 2:
The patent modifies the chemical parameters of bisphosphonate drugs by conjugating them with fatty acids of varying chain lengths and structures. This parameter change transforms the pharmacokinetic properties, improving oral bioavailability from less than 1% to significantly higher levels, while maintaining the therapeutic effect on bone resorption.
2Reliability
If anti-resorptive therapy is used, then early and mild osteoporosis is effectively treated, but advanced osteoporosis with massive bone loss is not adequately addressed
Solution Approach 1:
The patent creates compounds that perform multiple functions: they inhibit bone resorption through the phosphonate moiety while simultaneously stimulating bone formation through the fatty acid conjugate's interaction with osteoblasts. This multi-functionality allows the same compound to be effective in both early osteoporosis (anti-resorptive effect) and advanced osteoporosis (anabolic effect), resolving the limitation of current anti-resorptive therapies.
3Productivity
If teriparatide is used for bone anabolism, then bone formation is stimulated and fracture risk is reduced, but safety concerns and restricted use apply
Solution Approach 1:
The patent employs a different molecular approach (fatty acid-phosphonate conjugates) that achieves bone anabolic effects through a mechanism distinct from PTH-based therapies. These compounds act through alternative pathways that stimulate osteoblast differentiation and bone formation without the oncogenic risks associated with prolonged PTH receptor activation, providing a safer long-term solution for bone anabolism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oxysterol-bisphosphonate conjugates demonstrate enhanced osteogenic activity, improved bioavailability, and selective binding to hydroxyapatite, leading to robust bone formation and spine fusion in animal models, with potential for systemic administration as anabolic agents for osteoporosis treatment.
Implementation Method 1
selective binding to hydroxyapatite
Implementation Method 2
stimulate the Hedgehog signaling pathway
Data Source
AI summary
Oxysterol-bisphosphonate and oxysterol-alendronic acid compounds, compositions including them, and methods using them for the treatment of bone disorders.